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The homeostasis betweenmature neurotrophin NGF and its precursor proNGF is thought
to be crucial in physiology and in pathological states. Therefore, the measurement
of the relative amounts of NGF and proNGF could serve as a footprint for the
identification of disease states, for diagnostic purposes. Since NGF is part of proNGF,
their selective identification with anti-NGF antibodies is not straightforward. Currently,
many immunoassays for NGF measurement are available, while the proNGF assays
are few and not validated by published information. The question arises, as to whether
the commercially available assays are able to distinguish between the two forms. Also,
since in biological samples the two forms coexist, are the measurements of one species
affected by the presence of the other? We describe experiments addressing these
questions. For the first time, NGF and proNGF were measured together and tested in
different immunoassays. Unexpectedly, NGF and proNGF were found to reciprocally
interfere with the experimental outcome. The interference also calls into question the
widely used NGF ELISA methods, applied to biological samples where NGF and proNGF
coexist. Therefore, an immunoassay, able to distinguish between the two forms is
needed. We propose possible ways forward, toward the development of a selective
assay. In particular, the use of the well validated anti-NGF αD11 antibody in an alphaLISA
assay with optimized incubation times would be a solution to avoid the interference in
the measurement of a mixed sample containing NGF and proNGF. Furthermore, we
explored the possibility of measuring proNGF in a biological sample. But the available
commercial kit for the detection of proNGF does not allow the measurement of proNGF
in mouse brain tissues. Therefore, we validated an SPR approach for the measurement
of proNGF in a biological sample. Our experiments help in understanding the technical
limits in the measurement of the NGF/proNGF ratio in biological samples, and propose
concrete solutions toward the solution of this problem.
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INTRODUCTION
Nerve Growth Factor (NGF) (Levi-Montalcini, 1987), the
prototype neurotrophin (Bothwell, 2014), is required for the
development and maintenance of neurons in the central and
peripheral nervous system, as well as in non-neuronal systems,
and exerts its functions via TrkA and p75NTR receptors
(Hempstead et al., 1991; Chao and Hempstead, 1995; Fahnestock
et al., 2004a; Clewes et al., 2008; Paoletti et al., 2009).
NGF is translated as a precursor protein, proNGF, which is
processed in the Trans-Golgi Network by furin (Shooter, 2001),
and has complementary functions to its mature counterpart
(Hempstead, 2006). ProNGF is the main form of NGF in the
brain (Fahnestock et al., 2001; Bierl and Isaacson, 2007), and can
also be secreted as such and processed by extracellular proteases
(Lee et al., 2001; Bruno and Cuello, 2006). proNGF interacts
mainly with p75NTR and sortilin, and the interplay between these
receptors triggers cellular death (Nykjaer et al., 2004; Volosin
et al., 2006). It also interacts with TrkA, although with a reduced
affinity (Fahnestock et al., 2004a,b).
The homeostasis between the levels of mature NGF and
proNGF is emerging as a crucial factor in physiology and inmany
pathological states. For instance, in the adult brain, increased
amounts of proNGF have been associated to neurodegeneration
(Counts and Mufson, 2005), highlighting the importance of the
NGF/proNGF ratio as an upstream driver for neurodegeneration
(Capsoni and Cattaneo, 2006; Capsoni et al., 2010; Iulita and
Cuello, 2014; Counts et al., 2016).
Therefore, the NGF/proNGF levels in cerebrospinal fluid
(CSF) represents a target of clinical interest and a footprint
biomarker, to be exploited for diagnostic purposes in numerous
neuronal and non-neuronal pathologies (Iulita and Cuello, 2014;
Counts et al., 2016).
For many years, NGF levels have been measured in biological
fluids (Vizzard, 2000; Wang et al., 2010; Konukoglu et al.,
2012; Liu and Kuo, 2012; Tasset et al., 2012; Counts et al.,
2016) by ELISA, and a very large body of literature reports
on correlations between altered levels of “bona fide” NGF and
various pathological conditions (Vizzard, 2000; Lombardi et al.,
2008; Marksteiner et al., 2008; Wang et al., 2010; Konukoglu
et al., 2012; Liu and Kuo, 2012; Tasset et al., 2012; Ke et al.,
2014; Camara et al., 2015), without taking into consideration the
concomitant presence of proNGF in the same samples. However,
the open question remains, whether ELISA assays, exploiting
anti-NGF antibody pairs, really discriminate between the two
neurotrophin forms. Indeed, the possibility of discriminating and
measuring relative amounts of NGF and proNGF in biological
samples is hampered by the fact that mature NGF is part of the
proNGF protein, a simple fact that is most often overlooked.
Indeed, no evidence has been reported so far, providing a
demonstration whether or not the presence of the NGF precursor
is neutral to the measure of NGF, by the widely used NGF
immunoassays.
Given the interest of determining the proNGF/NGF ratios in
biological samples and motivated by the objective of developing
a method for the selective reliable detection of the two related
proteins, we set out to closely and systematically examine
currently available methods. We made use of a set of anti-
NGF and anti-proNGF antibodies, and validated our conclusions
both with recombinant proteins and with biological samples
from transgenic mice tissues. Although differences in the NGF
sequences from different species exist (Malerba et al., 2015), we
selected the mice samples as a validation model organism.
The different formats analyzed will be presented in this paper,
which produced a set of a priori unexpected results, and allowed
to identify major criticalities and the possible ways to overcome
the obstacles.
METHODS
Neurotrophins and proNGF Transgenic
Mouse Model
All the experiments were performed on the short forms of the
recombinant mouse proNGF, namely rm-proNGF25 (according
to the nomenclature reported in Paoletti et al., 2009). For the
sake of brevity, throughout the manuscript the protein was
simply named as proNGF. Accordingly, the mature protein was
named as NGF. proNGF and NGF were expressed and purified
as in Paoletti et al. (2009). The 280 nm absorbance of the
purified proteins in buffer was measured by using a UV-visible
spectrometer (Nanodrop). The concentrations were calculated
according to the Lambert–Beer law.
The biological source for the analyzed brain tissues was
the transgenic mouse TgProNGF#72 (Tiveron et al., 2013) and
its WT counterpart, the BDFN strain. The homogenation of
the brain extracts and the densitometric analysis were carried
out as described (Tiveron et al., 2013), unless where specified
differently.
Animal experiments were carried out according to Italian
legislation (DL 116/92) and European Communities Council
Directive (86/609/EEC). Studies were conducted under the
permit (number 3/2012, EBRI Foundation) approved by the
Italian National Committee for animal research.
Immunoprecipitation and Western Blot for
Measuring NGF and proNGF from
Transgenic and WT Mice Cortex
The immunoprecipitation (IP) andWestern Blot were performed
as previously described (Tiveron et al., 2013). Briefly, cerebral
corteces (CTX) were isolated from WT and transgenic
TgproNGF#72 mice. For each immunoprecipitation (IP), a
pool of four animals, divided into male and female, was used
and analyzed. Each pool of CTX was homogenized with 2ml of
Lysis buffer per g of tissue (Lysis Buffer: Tris HCl 0.1M, NaCl
0.4M, SDS 0.1%, Triton X-100 1%). The homogenates were
incubated in ice for 30min and then centrifuged for 30–40 min at
maximum speed. The total amount of protein in the supernatant
was quantified by Bradford Assay (SIGMA-Aldrich, St Louis,
MO, USA). The same amount of total protein samples (4mg)
was immunoprecipitated with a large excess of anti-NGF αD11
antibody before western blot. The whole samples after IP were
loaded onto the gel (Criterion, Bio-Rad, 4–12% Bis-Tris) for
western blotting. The primary antibody used was anti-proNGF
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 August 2016 | Volume 9 | Article 63
Malerba et al. NGF/proNGF Reciprocal Interference in Immunoassays
(Alomone) and the secondary antibody was goat anti-rabbit
HRP conjugated (Jackson laboratories). Recombinant proNGF
and NGF were used as control samples; loaded samples were in
the linear range of detection. The membrane was then stripped
and incubated with the primary antibody, anti-NGF M20 (Santa
Cruz). The intensity of the bands on the western blots from
three separate experiments was measured by densitometric
analysis using the software of the Kodak scanner. The net
intensity was normalized against the internal area of each
band and then compared with an internal standard of NGF or
proNGF.
ProNGF Interferes with the Determination
of NGF by Using Commercial ELISA
NGF Emax R© ImmunoAssay System Promega was initially
chosen to perform the experiments because it is one of the most
widely used commercial kits for NGF measurement.
The assay was carried out using either the mAb Promega,
as indicated in the manufacturer’s protocol, or the rat anti-
NGF mAb αD11 (Cattaneo et al., 1988) (0.5 µg/ml), as primary
antibody. All the other steps were carried out according to
manufacturer’s instruction.
In order to verify the specificity of the ELISA for NGF, a curve
of recombinant proNGF was carried out (10 pg/ml – 1µg/ml
range) (Supplementary Table S1). Moreover, two concentrations
of NGF (10 and 100 pg/ml) and proNGF (50 and 200 pg/ml),
spiked in the assay buffer, either alone or together with NGF, were
assayed (Tables 1, 2 and Figure 3).
TgProNGF#72 brain homogenates were measured at different
dilutions: 1:25, 1:50, 1:100, and 1:200. The tissue samples were
homogenized as described (Tiveron et al., 2013). Cortex brain
areas (CTX) were isolated from TgProNGF#72mice, 12 month
old. A pool of 8 transgenic animals (4 males and 4 females)
was used and analyzed. The concentration of the total protein
in the sample, measured by Bradford assay (Sigma-Aldrich), was
27 mg/ml. proNGF at the same concentrations assayed in assay
buffer, were spiked into TgProNGF#72 homogenate (1:25, 1:50,
1:100, and 1:200), and measured.
In order to verify the obtained results, two other commercial
kits (ChemiKine Nerve Growth Factor, Sandwich ELISA, from
Millipore, and Mouse NGF Rapid ELISA Kit from Biosensis)
were tested. The two concentrations of NGF (10 and 100 pg/ml),
and proNGF (50 and 200 pg/ml), either alone or together with
NGF, were assayed spiked in the assay buffer, supplied by
Promega.
TABLE 2 | NGF and proNGF spiked into brain cortex extract of proNGF#72
Transgenic Mouse assayed by Emax Promega with mAb Promega and
mAb αD11.
ProNGF spiked into brain
cortex extract of
proNGF#72 Transgenic
Mouse (Dil.1:200)
NGF Concentration obtained (pg/ml ±
Standard deviation)
Emax Promega with mAb
Promega
Emax Promega
with mAb αD11
0 290.04 ± 0.01 382.90 ± 0.06
proNGF 200 326.89 ± 0.03 380.24 ± 0.07
proNGF 50 351.12 ± 0.07 398.26 ± 0.03
The table reports the values of NGF concentration obtained from the samples of
proNGF#72 Transgenic Mouse cortex homogenate, spiked with 0, 50, and 200 pg/ml
of recombinant proNGF. In red the outliers values. The concentration of total protein of
the cortex brain extract was 27mg/ml, then diluted 1:200.
TABLE 1 | Recovery of NGF and proNGF spiked in the sample buffer (supplied by each supplier of the commercial kits).
ProNGF/NGF spiked
in sample buffer
(pg/ml)
Recovery % of proNGF or NGF spiked
Emax Promega with Emax Promega with Chemikine NGF Rapid
mAb Promega mAb αD11 Chemicon ELISA Biosensis
proNGF 200 0 45 9 0
proNGF 50 0 28 0 0
NGF 10 66 58 139 218
NGF 10 + proNGF 50 100 266 154 241
NGF 10 + proNGF 200 115 1391 390 339
NGF 100 82 92 180 532
NGF 100 + proNGF 50 140 195 180 427
NGF 100 + proNGF 200 86 257 210 479
The table synthesizes the results of the percentage of recovery of NGF and proNGF spiked separately and together into the assay buffer of the three different commercial kits for the
detection of NGF analyzed. The Promega kit was tested in the two different formats: rat mAb Promega and αD11. Two concentrations of recombinant NGF (10 and 100pg/ml) and
proNGF (50 and 200pg/ml) were spiked into the assay buffer either alone or together with NGF and measured by using the kits previously described. The percentage of recovery was
calculated on the spiked value of NGF and proNGF, if spiked alone, and on the spiked value of only NGF, in the sample containing both the precursor and mature form. Description of
the colored values for the recovery percentage of NGF, calculated for the mixed sample:
– red when the value was higher than the corresponding recovery percentage of NGF, spiked alone;
– black if the values were similar;
– blue if the recovery percentage of NGF, in presence of proNGF, was lower than the corresponding value of NGF spiked alone;
– the black bold values represent the outliers values.
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The experiments were repeated three times for Promega kit,
with both the antibodies, two times for Biosensis and Millipore
kits. The obtained values were compared to IP results indicated
in Figure 1B (The brain extracts used in the experiment were
derived from a mixed sample of 50% male and female, therefore
an average of the values, was considered).
NGF Emax R© ImmunoAssay System Promega and ChemiKine
Nerve Growth Factor, Sandwich ELISA Millipore were
purchased, while Mouse NGF Rapid ELISA Kit Biosensis
was kindly provided by Biosensis.
The statistical analysis was carried out by using a t-student
test. The interpolated values corresponding to samples spiked
with NGF and proNGF together were compared to the value
of samples spiked with NGF alone, measured with the same
ELISA kit.
ProNGF Interferes with the Determination
of NGF by Using in House ELISA
In order to asses an in-house NGF ELISA, a number of
different sandwich formats were tested by using both commercial
antibodies and antibodies produced in our lab: Anti-NGF mAb
αD11 (Cattaneo et al., 1988); Anti-NGF R&D no. MAB256; Anti-
NGF pAbM20, Santa Cruz no. sc-549; Anti-NGF pAbH20, Santa
Cruz no. sc-548; Anti-proNGF scFv FPro10 (Paoletti et al., 2012);
Anti-proNGF pAb Sigma no. P 5498; Anti-NGF pAb Sigma no.
N 6655.
The assay buffer was milk (Applichem) at a concentration
of 4%.
The concentration of the antibodies in coating (mAb
αD11) was 2 µg/ml in carbonate buffer. The concentration
of the primary was variable. It was assessed by following
the manufacturer’s instructions for commercial antibodies. The
Horse Radish Peroxidase (HRP) conjugated secondary antibodies
were used at the concentration suggested by the manufacturer’s.
The incubation times were different. For the calibration curves
and the samples, it varied from 15 to 30min, in the case of a
fast kinetics, for the primary antibody it was 1.5–2 h, for the
secondary antibody 1 h.
AlphaLISA (Perkin Elmer) for the Selective
Detection of NGF: Proof of Principle
AlphaLISA is a highly sensitive immunoassay, commercialized
by Perkin Elmer. In the AlphaLISA assay, a biotinylated
antibody, and an antibody-conjugated AlphaLISA Acceptor
beads are used to capture the target analyte. The biotinylated
antibody associates with an Alpha streptavidin-coated Donor
bead. When the analyte is present in the sample, the Donor
and Acceptor beads are brought together. Upon excitation,
a photosensitizer inside the Donor bead converts ambient
oxygen to an excited singlet state. Singlet oxygen diffuses
up to 200 nm to produce a chemiluminescent reaction in
the Acceptor bead, leading to light emission. The amount of
light is proportional to the amount of analyte present in the
sample.
First of all, the antibodies anti-NGF Mab αD11 (Cattaneo
et al., 1988) and Mab 4GA (Cattaneo et al., 1988; Covaceuszach
FIGURE 1 | IP and WB of transgenic and wild-type mice. (A): IP and WB
of cortex extracts from male (M) and female (F) TgProNGF#72 and wild-type
(WT) mice. IP on extracts from cortex (CTX) with anti-NGF αD11 antibody,
followed by WB with anti-NGF or anti-proNGF antibody, as described in
Tiveron et al. (2013). A representative WB probed with anti-proNGF (PAb
Alomone), (top) or anti-NGF M20 (Santa Cruz) (bottom) is shown.
TgproNGF#72 and wild type mice, male and female, were analyzed. (B)
Quantitative analysis of proNGF and mature NGF in the CTX of TgproNGF#72
mice, male and female, by IP and WB and densitometric analysis. After
anti-NGF IP, the proNGF bands, (in WB probed with anti-proNGF), and the
NGF bands, (in the WB probed with anti-NGF antibody), both identified also by
Mass Spectrometry, were quantified. The resulting intensities were normalized
against the area of the bands, and then compared with an internal standard of
recombinant proNGF and NGF. Loaded samples were in the linear range of
detection. Comparison between proNGF and NGF amounts in TgproNGF#72,
male and female, is reported in the histogram. The experiment was carried out
in triplicate.
et al., 2009) were conjugated to Biotin and to Acceptor
beads, respectively, in both the possible antibody/biotin or
antibody/acceptor combinations, following the Perkin Elmer
alphaLISA protocol.
The initial results allowed to choose the best configuration:
mAb αD11conjugated to acceptor beads and biotinylated
mAb 4GA.
The best order of addition and the concentration of the
reagents were also assessed:
• 5 µL of the analyte (NGF, proNGF or both),
• 10 µL of the biotinylated mAb 4GA (final concentration
1mM),
• 10 µL of the mAb αD11conjugated to acceptor beads (final
concentration 10 µg/mL),
• First Incubation,
• 25 µL of streptavidin Donor Beads (final concentration 40
µg/mL),
• Second Incubation in the dark.
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 August 2016 | Volume 9 | Article 63
Malerba et al. NGF/proNGF Reciprocal Interference in Immunoassays
NGF and proNGFwere assayed separately and together (dynamic
range: 2000–4 pg/ml, 1:2 dilutions, in duplicates). For each
test, three calibration curves were carried out, using purified
recombinant proteins as standards: NGF, proNGF, and both
neurotrophins in the same well, in the range from 4 to
2000 pg/ml. The dilution were done in AlphaLISA NaCl buffer
(Perkin Elmer).
In the first experiments, the first incubation was 60min, and
the second one 30min. Other assays were carried out, in which
the first incubation was 15, 30, or 60min, the second one 20min.
The signal was read on the Perkin Elmer instrument
EnVision R©.
Is There Interference of NGF on proNGF
Measurement by Using the Commercial
Available ELISA Kit?
The CUSABIO Mouse Pro-Nerve Growth Factor (proNGF)
ELISA Kit was purchased and tested. Mice brain areas were
isolated from 18 months old TgProNGF#72 and WT mice.
Two pools of 2 transgenic and 2 WT animals were used and
analyzed. The brain tissues were homogenized according to
manufacturer’s protocol. The total amount of protein in the
samples was quantified by Bradford Assay (Sigma-Aldrich). The
concentration of total protein measured was 3 mg/ml for both
transgenic andWTmice homogenates. The assay was carried out
according to manufacturer’s instruction.
The samples were homogenized according to the datasheet.
The samples assayed were:
– Serial dilution of TgProNGF#72 and WT brain samples
(Table 5) in CUSABIO sample buffer,
– Serial dilution of recombinant proNGF (Supplementary
Table S2) and NGF in CUSABIO sample buffer,
– Mice tissue spiked with recombinant proNGF (Table 6)
and NGF,
TgProNGF#72 and WT mice tissues of 18 months were
homogenized with the protocol described in Tiveron et al. (2013),
and a direct WB were carried out. 150µg of total protein
were loaded onto the gel (criterion, 4–12% Bis-Tris, 12 + 2).
The primary antibody used was anti-proNGF (PAb Chemicon
Millipore) and the secondary antibody was goat anti-rabbit HRP-
conjugated (Jackson).
Surface Plasmon Resonance Using
Biacore
The experiments were all performed with a Biacore 2000
equipment (GE healthcare).
In all the cases, the experiments were performed on CM5
chips with amine coupling. The coupling reaction was performed
with the specific kit provided by GE healthcare, according to
manufacturer’s instructions.
Different antibodies were used: two anti-NGF monoclonal
antibodies (the commercial mAb R&D 256 and mAb αD11,
Cattaneo et al., 1988); two anti-proNGF antibodies (the
commercial mAb Millipore, and mAb FPro10 derived in our
laboratory, Paoletti et al., 2012). The antibodies used as ligands
were immobilized at a 2000 RU surface concentration of the CM5
chip. The analyte proteins used in all kinetic experiments were
injected in PBS (Phosphate Buffer Saline) added with 5% BSA,
and at a flow rate of 30µl/min. The regeneration of the chip
was performed with a pulse (10µl) of 10mM Glycine pH 1.5.
The data analysis was carried out using the BIAevaluation 3.2
Software by Biacore.
For the sake of concentration measurements, report points
were placed at the beginning of the dissociation phase, in order
to avoid the bulk signal of the buffer.
For the test to reduce the aspecific binding of the biological
matrix to the chip, the following conditions were analyzed:
– sample boiling (10min),
– raising the ionic strength—addition of 250 mM NaCl to the
running buffer,
– competition with soluble dextran (Sigma), at a concentration
of 0.5mg/mL in the running buffer or of 10mg/mL in the
samples.
The biological samples analyzed were treated as described for the
ELISA assays.
RESULTS
Detection of NGF and proNGF from
Biological Sources by Immunoprecipitation
Followed by Western Blot: A Reference
Assay
The experiments described in this paper focused on mouse NGF
and proNGF, both as recombinant proteins and as proteins
derived from mouse brain tissues. In fact, the detection of the
neurotrophins remains a more difficult task in this species, with
respect to rat, and human samples, where a direct Western blot is
possible (Fahnestock et al., 2001).
The recombinant NGF and proNGF were produced and
purified as described (Paoletti et al., 2009). As a biological
source of NGF and proNGF, for these experiments we used the
transgenic mouse TgProNGF#72 and its wild-type counterpart
(WT) (Tiveron et al., 2013). This model was chosen because NGF
and proNGF are present together, but in larger amounts than in
the WT, facilitating their detection.
Immunoprecipitation followed by Western Blot (IP+WB) is
a reliable way, albeit of low sensitivity, to detect both NGF
and proNGF from biological samples. This approach can be
used as a reference, to separately determine the amounts of
NGF and proNGF bands in a sample. Samples of different
brain areas (Cortex, Basal Forebrain, and Hippocampus) of
TgProNGF#72 and WT mice were analyzed by IP+WB,
as described (Tiveron et al., 2013). A representative WB,
challenged both with anti-proNGF and anti-NGF, is shown
in Figure 1A. The amounts of NGF and proNGF, detected
in the cortex of the same transgenic mice, are indicated in
Figure 1B.
The levels of NGF detected by IP+WB detection of NGF in
these samples was compared to those detected by the currently
available ELISA assays.
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ProNGF Interferes with the Determination
of NGF by Commercial ELISA
Some commercially available ELISA assays were comparatively
analyzed in samples containing known amounts of recombinant
mouse NGF and proNGF (Paoletti et al., 2009). In the datasheets,
Promega Emax and Chemikine declare no cross reactivity with
other mature neurotrophins, without mentioning the specificity
with respect to proNGF. The possible cross-reactivity with
proNGF is reported in the NGF Biosensis datasheet, but is
declared to be unimportant, since it is only observed at high
protein concentration.
NGF Emax R© ImmunoAssay (Promega), one of the most
widely used commercial NGF immunoassay, was analyzed first.
The assays were carried out using, as primary antibodies, either
the Promega anti-NGF mAb, or our own anti-NGF mAb αD11
(Cattaneo et al., 1988). All other steps were carried out according
to manufacturer’s instruction.
Two calibration curves were obtained and interpolated
(Figure 2). A curve of proNGF was also performed, in order to
verify the extent of cross-reactivity with proNGF. ProNGF was
detected by Emax NGF Immunoassay, starting from 1000 pg/ml
(Supplementary Table S1). At lower concentrations, proNGF is
recognized only by mAb αD11.
Two concentrations of NGF and proNGF were spiked into
the assay buffer, either alone or together with NGF, in different
stoichiometric ratio (Table 1 and Figure 3). For both antibodies,
NGF-spiked samples yielded an acceptable recovery (Table 1
and Figure 3). proNGF spiked-samples were detected, with a
lower recovery, only by mAb αD11, thus confirming the results
reported in Supplementary Table S1.
Unexpectedly, when proNGF and NGF were spiked together,
the interpolated values did not correspond to those obtained for
NGF alone. So, despite the fact that the assay did not detect
proNGF at these low concentrations, the presence of proNGF
altered significantly the measurement of NGF. This interference
was not antibody-dependent, since it was observed with both
Promega and αD11 anti-NGF mAbs, although αD11 detected
proNGF better than mAb Promega.
In order to verify whether this interference was due to the
specific layout of the Promega kit, the NGF/proNGF spiking
experiments were carried out also with two other commercial
kits: ChemiKine NGF Sandwich ELISA (Millipore), and Mouse
FIGURE 2 | Emax NGF Promega: NGF Standard curves. NGF standard curves carried out by using rat mAb Promega (triangles) and mAb αD11 (Cattaneo et al.,
1988) (squares) as primary antibody.
Frontiers in Molecular Neuroscience | www.frontiersin.org 6 August 2016 | Volume 9 | Article 63
Malerba et al. NGF/proNGF Reciprocal Interference in Immunoassays
FIGURE 3 | NGF and proNGF spiked in the sample buffer (supplied by each supplier of the commercial kits). The histograms summarize the results of the
NGF and proNGF spiked separately and together into the assay buffer of the three different commercial kits for the detection of NGF analyzed. The Promega kit was
tested in the two different formats: rat mAb Promega and αD11. Two concentrations of recombinant NGF (10 and 100pg/ml) and proNGF (50 and 200pg/ml) were
spiked into the assay buffer either alone or together with NGF and measured by using the kits previously described. (A) (Emax Promega with mAb Promega), (B)
(Emax Promega with mAb αD11), (C) (Chemikine Chemicon), (D) (NGF Rapid ELISA Biosensis) report the values of concentration, interpolated by the calibration
curves. The calculated values of the samples spiked with both NGF and proNGF were compared to the spiked value of only NGF. The t-student test was carried out
and the p-values were calculated. Two asterisks on the histograms mean a p < 0.001.
NGF Rapid ELISA (Biosensis). With both assays, proNGF is
poorly detected if tested alone, while NGF alone is largely
overestimated, especially by the Biosensis ELISA (Table 1).
Remarkably, in both cases, the presence of proNGF markedly
interfered with the NGF measurement. Both for the Millipore
and Biosensis kit, proNGF altered NGF detection particularly at
high spiking concentrations, while the interference is less evident
for the 50 pg/ml spiking (Table 1 and Figure 3). In the conditions
tested, both kits confirmed what had been observed with the
Promega assay.
Thus, in the four different layouts tested, the presence of
proNGF altered significantly the measurement of NGF.
The same concentrations of proNGF (50 and 200 pg/ml)
were also spiked into diluted brain extracts from TgProNGF#72,
either alone or together with NGF (Table 2). The spiked extracts
were assayed with the Promega kit, using both Promega and
αD11 mAbs, as primary antibodies and the results are reported
in Table 2. Curves at different brain extract dilutions were
performed and the results obtained with the higher dilution of
mouse samples are reported (Table 2).
Surprisingly, all the interpolated values were out of scale.
The biochemical analysis on TgProNGF#72 cortex, carried out
by IP+WB (Figures 1A,B), demonstrated that the amount of
NGF in that sample was about 5 ng/mg of total protein. In
the same analysis, proNGF was estimated at 32 ng/mg of total
protein. Therefore, in the samples analyzed by ELISA (100 µL
of TgProNGF#72 cortex diluted 1:200), the total amount of
NGF should be about 70 pg. This estimated NGF value is in the
calibration curve concentration range and should be correctly
revealed by the assay. On the contrary, the interpolated values
were largely out of scale. These results confirmed those obtained
with the spikings in assay buffer, leading to the conclusion that
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the presence of proNGF interferes with the determination of
NGF by ELISA.
We conclude that the currently available commercial NGF
assays cannot give a reliable measure for NGF, when proNGF
is also present in the sample. This aspect cannot be considered
negligible, because most natural samples are likely to contain
bothNGF and proNGF (Fahnestock et al., 2001; Bierl et al., 2005).
ProNGF Interferes with the Determination
of NGF by Ad hoc ELISA Formats
In the attempt to solve the interference effects described above
and develop an ELISA for the differential detection of proNGF
and NGF, a number of different ad hoc sandwich formats
were tested, using both commercial antibodies and antibodies
produced in our lab (See Section Methods).
In particular, the specific differential kinetics for NGF and
proNGF of the anti-NGF mAb αD11 was exploited. mAb αD11
binds NGF very fast and dissociates very slowly (sub-pM KD)
(Paoletti et al., 2009). On the contrary, proNGF is also rapidly
bound by mAb αD11, but is released very rapidly, resulting in
a nM KD (Paoletti et al., 2009).
Due to these kinetic features of anti-NGF mAb αD11, after
a short incubation, NGF should be completely captured by
the antibody and remain stably bound, while proNGF should
dissociate and be washed away. Table 3 reports all the formats
tested, using mAb αD11 as the coating antibody, with a short
incubation time. These formats were also affected by interference.
The values obtained with proNGF and NGF together were
different from the sum of the values of the two neurotrophin
forms, assayed separately. In all cases, there was not a well-
defined interference trend, since the obtained values depend on
the relative input ratio and on the concentrations of the two
neurotrophin forms.
The interference was also observed with a different assay
format, by pre-clearing the sample with an anti-proNGF
antibody andmeasuring free NGF in the flow through (Figure 4).
In conclusion, interference betweenNGF and proNGF appears to
be a general phenomenon, independent of the specific formats of
the assay.
ProNGF Interferes with the Determination
of NGF by Surface Plasmon Resonance
(SPR)
Surface Plasmon Resonance (Christensen, 1997; Quinn
et al., 1997; Frostell-Karlsson et al., 2000; Gillis et al., 2002;
Samsonova et al., 2002; Kure et al., 2005; Yang et al., 2005;
Thillaivinayagalingam et al., 2007; Mytych et al., 2009) was
pursued as an alternative to sandwich ELISA.
CM5 chips with amine coupling chemistry were used in the
direct binding format (antibodies as chip-bound ligands and
neurotrophins as analytes).
Different anti-NGF and anti-proNGF antibodies were
immobilized on the surface. The use of both anti-NGF and
anti-proNGF antibodies should make it possible, in principle,
to measure NGF and proNGF in a sample in parallel. Different
surface densities were tested, to identify the best conditions for
the immunoassay (not shown).
At first, calibration curves were measured, using recombinant
proNGF andNGF flowing over the various antibodies (Figure 5).
Well-behaved calibration curves were obtained for the binding
of mature NGF to anti-NGF antibodies (Supplementary Figure
S1). However, since these antibodies recognize also proNGF
(Figures 5C,D), this format cannot be used for the direct
detection of mature NGF from a mixture of NGF and proNGF.
As for proNGF, calibration curves could be determined
for proNGF with the two anti-proNGF antibodies, with good
TABLE 3 | In house ELISA for the detection of NGF (Exploiting the mAb αD11 fast kinetics).
SCHEME
Coating Primary Sensitivity Observations
mAb αD11 H20 Santa Cruz ng/ml Test with recombinant NGF and proNGF, separately and together.
Different ratio assayed.
The values corresponding to proNGF and NGF together are different from the sum of the
values of the neurotrophins, assayed separately. There is not a clear trend, the values
depend on the relative ratio of the neurotrophins.
The anti-proNGF gave a signal, demonstrating that the proNGF was not completely washed
away and interferes with NGF detection.
M20 Santa Cruz
Anti-NGF Sigma
Anti-proNGF Sigma
Anti-proNGF scFV FPro10
ELISA sandwich format based on the kinetic of mAb αD11. After 15–30 min, based on the respective association and dissociation constants, only NGF should remain tightly bound to
αD11, while proNGF should be washed out.
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FIGURE 4 | ELISA for the differential detection of NGF and ProNGF. (A) Strategy: capture NGF and measure proNGF (Exploiting the mAb αD11 fast kinetics).
ELISA sandwiches format based on a pre-capturing of NGF by a treatment of the sample with mAb αD11 (Cattaneo et al., 1988) on a solid support. Subsequent
(Continued)
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FIGURE 4 | Continued
detection of proNGF by traditional sandwich ELISA. Antibodies tested in different combinations: Anti-NGF pAb H20 (Santa Cruz no. sc-548), Anti-proNGF scFV
FPro10 (Paoletti et al., 2012), Anti-NGF pAb M20 (Santa Cruz no. sc-549), Anti-NGF pAb (Sigma no. N 6655), Anti-proNGF pAb (Sigma no. P 5498), mAb αD11
(Cattaneo et al., 1988), Anti-NGF mAb 256 (R&D no. MAB256). (B) Strategy: capture proNGF and measure proNGF (Exploiting anti—proNGF antibodies in ELISA
sandwich). Antibodies tested in different combinations: Anti-proNGF scFV FPro10 (Paoletti et al., 2012), mAb αD11 (Cattaneo et al., 1988), Anti-NGF pAb M20 (Santa
Cruz no. sc-549), Anti-proNGF Novus (no. S-080-100), Anti-NGF mAb 256 (R&D no. MAB256), Anti-proNGF mAb (clone EP1318Y) (Millipore no. 04-1142),
Anti-proNGF pAb Chemicon (Millipore no. AB9040), Anti-proNGF pAb Alomone (no. ANT-005), Anti-NGF Abnova (no. PAB0755).
FIGURE 5 | SPR analysis—calibration curves obtained with proNGF and NGF over the panel of different antibodies. (A) Different proNGF concentrations
tested on anti-proNGF mAb FPro10. Concentrations in nM (from top): 500, 333, 222, 148, 98, 65, 33, 16, 8, 4, 2, 1, 0.5; (B) Different proNGF concentrations tested
on anti-proNGF mAb Millipore. Concentrations in nM (from top): 500, 333, 222, 148, 98, 65, 33, 16, 8, 4, 2, 1, 0.5; (C) Different proNGF concentrations tested on
anti-NGF mAb αD11. Concentrations in nM (from top): 500, 333, 222, 148, 98, 65, 33, 16, 8, 4, 2, 1, 0.5; (D) Different proNGF concentrations tested on anti-NGF
mAb R&D. Concentrations in nM (from top): 100, 50, 25, 12.50, 6.25, 3.2, 1.6, 0.8, 0.4, 0.2, 0.1; (E) Different NGF concentrations tested on anti-NGF mAb R&D.
Concentrations in nM (from top): 100, 50, 25, 12.50, 6.25, 3.2, 1.6, 0.8, 0.4, 0.2, 0.1.
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reproducibility and concentration range (Figures 5A–D,
Supplementary Figure S2). The best sensitivity (0.1 nM) was
achieved for the Millipore anti-proNGF (Supplementary
Figure S2), while it was 0.5 nM for anti-proNGF
mAb FPro10.
To increase the sensitivity of the assay and to measure
NGF specifically, a number of different sandwich formats, with
different antibody combinations, were tested, including the use
of Protein L (Svensson et al., 1998) to capture the αD11 anti-
NGF antibody. No significant improvement was obtained (data
not shown). Therefore, the direct measurement was used for all
following experiments.
A test was made, to verify whether NGF and proNGF, mixed
together, interfere with each other, when detected by SPR. As
shown in Figure 6, the results obtained for a mixture of NGF
and proNGF are not equivalent to the sum of the results obtained
for the two proteins alone. The presence of both neurotrophin
forms in a sample gives rise to an interference effect. This is
detected as a higher response signal (solid lines in Figure 6)
compared to the theoretical sum of the experimental curves
of the single components (dotted lines of the corresponding
color in the Figure 6). This interference effect is variable,
depending on the relative ratio of the two proteins in the sample.
While for the anti-proNGF antibodies (mAb FPro10 and mAb
Millipore) this effect is negligible (Table 4), the interference
effect was more significant for the anti-NGF mAb αD11
(Table 4).
In conclusion, as for the ELISA, NGF and proNGF mixtures
do not behave in a linear way, since the response measured over
an anti-NGF antibody is not simply additive. The measurement
always overestimates the NGF value in the mixtures, although
the percentage of overestimation is variable, depending on
the NGF/proNGF ratio. However, it is noticeable that the
interference effect, in this case, is significantly lower than that
affecting the ELISA assay and has always the same sign. On the
other hand, the measures of proNGF with both anti-proNGF
antibodies tested in SPR were less affected by the interference
of the mixtures and thus gave reliable results also in the case of
mixtures. Thus, SPR represents a promising and better starting
point to develop an assay for the specific detection of NGF and
proNGF from samples in which the two proteins are mixed (See
below).
AlphaLISA for the Selective Detection of
NGF: Proof of Principle
AlphaLISA is a highly sensitive immunoassay technology (Perkin
Elmer) (PerkinElmer, 2008). AlphaLISA experiments were
carried out, using the anti-NGFmAb αD11 (Cattaneo et al., 1988)
conjugated to acceptor beads and the biotinylated anti-NGFmAb
4GA (Covaceuszach et al., 2009). proNGF was not detected,
when assayed alone (Figures 7A,B). With the longer incubation
times, also in this case, we observed interference of proNGF on
the NGF measurement (Figures 7A,B). However, surprisingly,
this interference decreased by shortening the incubation time.
Indeed, for the 15 min incubation data, the curves of NGF alone
and of the mix of the two neurotrophin forms were almost
overlapped (Figure 7B). Thus, with AlphaLISA we have found
conditions that minimize the perturbing reciprocal interference
of NGF and proNGF.
Is There Interference of NGF on proNGF
Measurement by Using the Available
Commercial ELISA Kit?
Similarly to what we did for NGF, we tested the only
commercially available proNGF ELISA kit (Mouse proNGF
ELISA Kit CUSABIO), in order to assess if there is also an
interference of NGF on proNGF measurement. We chose the
Mouse proNGF ELISA Kit CUSABIO, because it is the only
one in which the datasheet indicates that the assay is applicable
to mouse tissue homogenates, despite it does not indicates
which ones.
We chose to firstly measure proNGF in the brain of
TgProNGF#72 and WT mice in order to validate the assay.
The raw data obtained were good, with low standard
deviation between duplicates (Supplementary Figure S3). The
measured values did not follow the dilution factor, neither for
TgProNGF#72 nor for WT brain tissues (Table 5). Moreover,
the interpolated values were similar between transgenic and WT
samples, while TgProNGF#72 mice brain contains considerably
more proNGF than the WT, as determined by IP+WB. As
evident from Supplementary Table S2, the assay did not detect
recombinant proNGF. In all the cases tested, the assay did not
recognize NGF, as expected (not shown).
The brain tissue from TgProNGF#72 mice and from the
WT, spiked with proNGF, gave results similar to those obtained
without spiking (Table 6).
To confirm that the results of the assay were not due to an
intrinsic problem of the biological samples used, the same mouse
tissues were analyzed by WB. The assay confirmed the presence
of proNGF in TgProNGF#72, as expected (data not shown).
We can conclude that this assay is not applicable to brain
tissue homogenates. Moreover, it does not detect recombinant
proNGF. An explanation for the last issue might be that the
datasheet specifies that the curve must be carried out only by
using the undefined standard protein supplied with the kit (which
we did in parallel).
For these reasons, the interference of proNGF on NGF
measurement could not be evaluated for this proNGF ELISA.
Surface Plasmon Resonance (SPR) Assay
for the Selective Detection of proNGF:
Proof of Principle
The positive results obtained by SPR with anti-proNGF
antibodies, showing the absence of interference in mixtures
of recombinant NGF and proNGF (Figure 6) prompted
us to test SPR for the selective detection of proNGF in
biological samples. This is particularly relevant, since use of
the only commercially available proNGF ELISA kit (Mouse
proNGF ELISA Kit CUSABIO) consistently and convincingly
showed that it is not applicable to brain tissue extracts
(Tables 5, 6).
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FIGURE 6 | Binding analysis of NGF and proNGF mixtures to different antibodies. The following antibodies were immobilized on the chip for SPR experiments.
(A) anti-proNGF mAb FPro10; (B) anti-proNGF mAb Millipore; (C) anti-NGF mAb αD11. In all the panels, the curves represent the following analytes from top to
bottom: 200 nM proNGF + 20 nM NGF (solid blue line, experimental value); 200 nM proNGF (solid yellow line, experimental value); 200 nM proNGF + 20 nM NGF
(Continued)
Frontiers in Molecular Neuroscience | www.frontiersin.org 12 August 2016 | Volume 9 | Article 63
Malerba et al. NGF/proNGF Reciprocal Interference in Immunoassays
FIGURE 6 | Continued
(segmented blue line, theoretical value); 40 nM proNGF + 20 nM NGF (solid purple line, experimental value); 40 nM proNGF (solid orange line, experimental value);
40 nM proNGF + 20 nM NGF (segmented purple line, theoretical value); 20 nM proNGF + 20 nM NGF (solid green line, experimental value); 20 nM proNGF (solid red
line, experimental value); 20 nM proNGF + 20 nM NGF (segmented green line, theoretical value); 20 nM NGF (solid dark blue line, experimental value). The segmented
lines represents the theoretical curves for the point-to-point algebraic sum of the experimental curves of the single components, at the concentrations indicated.
TABLE 4 | Calculations of the theoretical value of the measured RU for the single NGF or proNGF components and comparison to the experimental one.
Sample Anti-proNGF FPro10 Anti-proNGF Millipore Anti-NGF mAb αD11
(% of the theoretical value) (% of the theoretical value) (% of the theoretical value)
20 nM proNGF + 20 nM NGF 112 105 166
40 nM proNGF + 20 nM NGF 101 97 111
200 nM proNGF + 20 nM NGF 103 100 108
TgProNGF#72 mice were used as a source of NGF and
proNGF in a biologically relevant context. Dilutions of the
whole brain homogenates were made, in order to find the
lowest possible interference by the sample matrix and avoid
the saturation of the system (not shown). A specific signal
for proNGF was detected, significantly higher in samples
from TgProNGF#72 mice than from WT mice (Figures 8A,B).
However, the difference between the signals from the transgenic
and WT samples was lower than expected, on the basis of the
proNGF levels determined by IP+WB (Figure 1A) (Tiveron
et al., 2013). Thus, a very high non-specific binding, to the
dextran chip surface, by molecules in the extract different
from the neurotrophins, was observed. A number of different
conditions were tried, to reduce non-specific binding. Among
these: blocking with BSA, heat denaturation of the samples,
in order to better expose the epitope, increase of buffer ionic
strength, addition of dextran as a soluble competitor, either in
the buffer or in the samples. However, none of these conditions
gave significant improvements in the non-specific component of
the signal (not shown). The only exception was dextran, which
slightly improved the results (not shown).
Despite the difficulty in reducing completely the non-specific
component of the binding, the difference in proNGF amount in
transgenic vs. WT animals could be measured by subtraction of
the two curves (Figures 8A,B—inserts). The average calculated
concentrations of proNGF in the brain extract, after subtraction
of the WT mice signal, from the TgProNGF#72 one, were:
100 nM using FPro10 mAb as detecting antibody; 10 nM using
anti-proNGF mAb Millipore. The reference value measured
from the same TgProNGF#72 brains, by IP+WB, was 20 nM.
Thus, the proNGF amounts calculated by SPR are of the same
order of magnitude of those obtained using the IP+WBmethod,
with some differences in the detection by the two proNGF
antibodies. These differences could be ascribed to the different
epitopes recognized.
These experiments provide a validated proof of principle, for
the application of the SPR technique for proNGF measurements
with anti-proNGF antibodies on the chip, and show a
promising way in future experiments, for the optimization of
the assay.
DISCUSSION
Measuring the relative amounts of NGF and proNGF using
sensitive and specific immunoassays would be crucial for
diagnostic purposes (Capsoni et al., 2000; Fahnestock et al.,
2001; Counts and Mufson, 2005; Capsoni and Cattaneo, 2006;
Tiveron et al., 2013; Chen et al., 2014; Iulita and Cuello, 2014;
Zhu et al., 2016). While different immunoassays to measure
NGF are currently available (See Section Methods), no validated
immunoassay for proNGF has been reported so far. A recent
report on the measurement of proNGF lacks proper controls in
the set-up of the assay (Soligo et al., 2015).
One of the aims of this work was to assess if the currently
available methods for measuring NGF are affected by the
presence of proNGF in the same sample of NGF, and vice
versa. We found, very surprisingly, that the concomitant
presence of NGF and proNGF in a sample dramatically alters
the measurement of the individual proteins. This interference
effect is demonstrated both with recombinant purified NGF
and proNGF in buffer and with NGF and proNGF from
biological samples. Three different techniques (ELISA, SPR, and
alphaLISA) have confirmed the interference, to a different extent
for the different methods. Moreover, we set the methodological
foundations for new immunoassays for the selective detection
of NGF or proNGF, avoiding this interference: alphaLISA for
NGF and SPR for proNGF measurements. The results clearly
show that by using these methods, and the conditions found, the
interference effect becomes negligible.
The results presented here clearly demonstrate that when
proNGF is added to NGF, the amount of NGF detected by current
immunoassay methods is neither equal to that of NGF alone,
nor to the simple sum of the two proteins. Depending on the
chosen antibody (Supplementary Table S3), and on the relative
concentrations of the two proteins, the measured outcome can
be additive or altered in unpredictable directions and thus not
possible to be evaluated. In any case, this interference had been
hitherto not described. Therefore, caution should be taken when
analyzing NGF in a biological sample and when interpreting
the large amount of data in the literature. When a quantitative
analysis of the two neurotrophins is described, it is important to
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FIGURE 7 | AlphaLISA experiments: curves of NGF, proNGF, mix of NGF + proNGF, comparison at different incubation times. Curves of NGF, proNGF, mix
of NGF + proNGF, linearly interpolated. NGF and proNGF were assayed separately and together (dynamic range: 2000–4pg/ml, 1:2 dilutions, in duplicates), in
different stoichiometric ratio. The dilution were done in AlphaLISA NaCl buffer (Perkin Elmer). The protocol is described in the methods sections and called for two
incubation times. In (A) the first incubation time lasted 60 min and the second one 30 min, as suggested by the manufacturer’s protocol. In (B), a comparison
between different incubation times is shown. The first incubation time was 15, 30, or 60min, while the second one was 20 min for all the curves. The signal was read
on the Perkin Elmer instrument EnVision®.
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TABLE 5 | ProNGF CUSABIO kit: serial dilution of the samples derived from brain extract of TgProNGF#72 and WT mice.
Samples Dilution Calculated concentration (pg/ml) Moltiplicated for dilution factor (pg/ml) OD 450 nm ± Standard deviation
TgproNGF#72 1:100 76.0 7596.2 0.1615± 0.006
1:50 88.1 4407.2 0.1835± 0.004
1:25 98.6 2465.1 0.202± 0.004
1:12.5 111.3 1391.2 0.224± 0.008
1:2 177.6 355.2 0.332± 0.007
WT 1:100 89.8 8982.7 0.1865± 0.012
1:50 107.5 5375.7 0.2175± 0.002
1:25 162.3 4057.1 0.308± 0.075
1:12.5 165.8 2072.0 0.3135± 0.006
1:2 266.6 533.2 0.4625± 0.071
The table reports, for each dilution of the samples, the values of concentration of proNGF, simply interpolated, multiplicated for the dilution factor, and the raw data of OD at 450 nm.
TABLE 6 | proNGF CUSABIO kit: Spiking of recombinant mouse proNGF
into TgProNGF#72and WT mice brain samples.
Spiking in: (1:100 dilution) Spiking of proNGF
(pg/ml)
Interpolated value
(pg/ml ± Standard
deviation)
TgproNGF#72 750 61.6 ± 0.006
94 60.8 ± 0.001
0 76.0 ± 0.006
WT mice 750 78.43 ± 0.001
94 80.91 ± 0.006
0 89.8 ± 0.012
Two concentration (750 and 94pg/ml) of recombinant proNGF were spiked into
TgproNGF#72 and WT mice brain tissues (1:100 dilution). The interpolated values
obtained were compared to the non-spiked sample.
clarify if the techniques employed are able to distinguish between
NGF and proNGF. Moreover, if NGF and proNGF co-exist
in the analyzed samples (as most often in biological samples),
the absence of interference should be demonstrated with the
techniques used, in order for the measurement to be considered
reliable. Although we focused in this paper on samples from
mouse origin and from recombinant mouse NGF and proNGF,
we are quite confident that our observations can also be extended
to human samples, since we observed the same kind of behavior
with the recombinant human proteins (not shown).
This interference effect was higher in ELISA assay, than in
SPR. This could be explained taking into consideration that
ELISA technique operates at steady-state, while SPR is measuring
in a kinetic mode. Therefore, the kinetic properties of the
antibodies could help in preventing significant interfering effects
in SPR.
The SPR results clearly show that this technique can be used
to develop a valid assay for the measurement of proNGF. Some
technical problems due to the high background by interference
of unknown components of the biological sample still need to be
addressed, before a reliable and sensitive assay can be released,
but the presented results show the way forward.
As for the alphaLisa measurements of NGF, the results
clearly showed that with a short incubation the interference
was virtually abolished, while the interference was higher with
longer incubation times. This promising result toward the clean
measurement of NGF, in a mixture with proNGF, is most likely
due to the differential kinetics properties of mAb αD11 vs. NGF
and proNGF (Paoletti et al., 2009). After a short incubation,
NGF was captured by mAb αD11 and remained stably bound,
while proNGF was not revealed. The same strategy that failed
in the classical ELISA format (See above), worked, instead, in
the alphaLISA set up. In this case, mAb αD11 was not fixed to
a solid support, as it was in the ELISA setting, and therefore
was not at limiting concentrations, but at a concentration high
enough to quantitatively capture NGF. In these conditions, the
fast kinetic avoided the binding of proNGF. The very promising
alphaLISA approach should be now tested and validated for the
measurement of NGF in biological samples.
All the results indicated that the coexistence of proNGF
and NGF in the same sample alters the correct selective
measurement of one of the two molecules. This issue, on one
hand, complicates the development of a good assay, but, on
the other hand, opens important and interesting biological
questions. Is there a molecular cross-talk between precursor and
mature neurotrophin forms, possibly involving the formation of
NGF/proNGF supramolecular structures, similar to the recently
described NGF dimer of dimer? (Covaceuszach et al., 2015). Does
the nature of this oligomeric cross-talk depend on NGF/proNGF
ratio? The answer to these questions arises from the interesting
interplay between the components of the system and careful
investigations will be required to give a definitive answer. Finally,
it could be interesting to investigate whether this interference
is typical of the NGF/proNGF system or if it could involve also
other pro-neurotrophins and their mature forms, for which there
is also a need to develop fully validated assays.
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